CHIMERA BIOSCIENCE INC.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
Utilizing transposase for stable clone establishment, CHIMERA BIOSCIENCE INC.’s method offers higher safety, stability, and yield compared to current mainstream antibiotic selection or lentiviral methods. This approach is highly suitable for peptide therapeutics, including recombinant proteins and antibody drugs. Through CHIMERA BIOSCIENCE INC.’s collaboration with Bora Biologics, the established stable clones can be transitioned to Bora Biologics for industrial-scale protein production.
CHIMERA BIOSCIENCE INC. also develops viral gene delivery systems for cell and gene therapies, including adenovirus-based transposase/CRISPR-Cas editing systems and industrial-grade manufacturing processes for adeno-associated virus (AAV).
For monoclonal antibody production, CHIMERA BIOSCIENCE INC. goes beyond traditional hybridoma technology. We can perform direct screening from B cells following antigen-induced immune responses. Alternatively, we can construct phage display libraries from antibody VAB fragments for direct screening against target antigens. Furthermore, this process can directly generate CHO cell lines to facilitate subsequent scale-up production, significantly shortening development timelines and reducing costs.
Other core expertise of CHIMERA BIOSCIENCE INC. includes CRISPR/Cas gene editing, recombineering systems based on homologous recombination principles, and phage display library construction and screening for the identification of peptide drug candidate leads.
(The content above was translated by AI.)
CHIMERA BIOSCIENCE INC. also develops viral gene delivery systems for cell and gene therapies, including adenovirus-based transposase/CRISPR-Cas editing systems and industrial-grade manufacturing processes for adeno-associated virus (AAV).
For monoclonal antibody production, CHIMERA BIOSCIENCE INC. goes beyond traditional hybridoma technology. We can perform direct screening from B cells following antigen-induced immune responses. Alternatively, we can construct phage display libraries from antibody VAB fragments for direct screening against target antigens. Furthermore, this process can directly generate CHO cell lines to facilitate subsequent scale-up production, significantly shortening development timelines and reducing costs.
Other core expertise of CHIMERA BIOSCIENCE INC. includes CRISPR/Cas gene editing, recombineering systems based on homologous recombination principles, and phage display library construction and screening for the identification of peptide drug candidate leads.
(The content above was translated by AI.)
Founded Year
2016
Unified Business No.
52249538
Status
Active
Number of Employees
0
Total Paid-in
Capital
25,035,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
CHIMERA BIOSCIENCE INC. is a biotechnology company engaged in drug discovery. It provides assistance in drug development (especially macromolecule drugs) while also developing novel therapies of its own, including gene therapy and cell therapy. In addition to continuing to provide in vitro (ex vivo) and in vivo disease model-based services and consultations—including drug screening for drug repositioning, target identification, pathogenesis research, drug screening, and pharmacological analysis—we also utilize genetic engineering technology to develop lead screening, selection, and characterization for macromolecules (proteins, antibodies, nucleic acids, and gene therapies), and collaborate with a CDMO (Bora Biologics) to ensure that the stable cell lines we manufacture for drug production can seamlessly transition to GMP-grade large-scale production. We also continue to provide customized genetically modified cell line services. In addition to the direction of macromolecule drug development, our current development focus is also on stem cell therapy, primarily targeting technologies required for cell and gene therapy development, clinical applications of stem cells, and other regenerative medicine-related technologies or products. We look forward to launching related patent licensing, products, or services.
(The content above was translated by AI.)
(The content above was translated by AI.)
